Exosomes vs. Stem Cells: What Practitioners Need to Know Before Integrating Either

Exosomes vs. Stem Cells: What Practitioners Need to Know Before Integrating Either

Stem Nova Network
Biologics Education
By Stem Nova Network · October 2026 · 10 min read

Exosomes and mesenchymal stem cells (MSCs) both fall under the regenerative biologics umbrella, but they are fundamentally different in biology, regulatory classification, storage requirements, and how they fit into a practice workflow. Exosomes are nanoscale extracellular vesicles (30–150 nm) released by cells — they carry signaling cargo but cannot replicate. MSCs are living cells derived from tissues such as umbilical cord Wharton's jelly — they are capable of self-renewal and differentiation. For licensed practitioners evaluating which category to integrate, understanding these distinctions is essential for informed sourcing, proper handling, and compliant documentation.

Why this comparison matters now: As both product categories gain traction across medspa, orthopedic, hair restoration, and wellness verticals, practitioners frequently encounter overlapping marketing language that blurs the line between them. This article defines each category on its own terms, maps the quality benchmarks worth evaluating, and identifies the documentation every practitioner should request from a supplier — regardless of which product they source.

What Are Exosomes?

Exosomes are a subclass of extracellular vesicles (EVs), typically 30–150 nanometers in diameter. They form inside multivesicular bodies within cells and are released into the extracellular space. Exosomes carry a cargo of proteins, lipids, and nucleic acids — including microRNA — that reflects the parent cell's environment and activity.

Key characteristics that define exosomes as a product category:

  • Cell-free: Exosomes are not living cells. They do not replicate, differentiate, or engraft into tissue.
  • Nanoscale: At 30–150 nm, they are roughly 100–500 times smaller than a human cell.
  • Source-dependent: The parent cell type, culture conditions, and passage number all influence what an exosome carries. Two exosome products from different manufacturing environments are not interchangeable.
  • Countable: Nanoparticle Tracking Analysis (NTA) provides a verified particle count per vial, which is one of the most objective quality benchmarks available for this category.

In the context of Stem Nova Network's product line, exosome biologics (60 Billion, Dermal Papillary Secretome Matrix+ 150B) are classified and labeled for topical cosmetic use only. They are manufactured in a 3D bioreactor environment, NTA-verified for particle concentration, and released with dual-lab Certificates of Analysis (COAs).

What Are Mesenchymal Stem Cells (MSCs)?

Mesenchymal stem cells — more precisely, mesenchymal stromal cells — are living, multipotent cells capable of self-renewal. When sourced from umbilical cord tissue (UCT), they are classified as human cells, tissues, or cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. The International Society for Cellular Therapy (ISCT) defines MSCs by three minimum criteria: plastic adherence, expression of specific surface markers (CD73, CD90, CD105), and tri-lineage differentiation capacity.

Key characteristics that define UCT-MSCs as a product category:

  • Living cells: MSCs are viable, replicating cells. Viability at the time of use is a critical quality metric — Stem Nova Network's hUCT-MSC products typically show 95–98% viability, verified on each lot COA.
  • Tissue-sourced: Wharton's jelly from first-pregnancy umbilical cord tissue provides a young, ethically donated cell source with documented donor eligibility under 21 CFR Part 1271 Subpart C.
  • Passage-sensitive: Cell quality degrades with excessive replication. Cumulative population doublings measure how many times a cell line has divided since isolation — fewer doublings generally indicate a younger, less-expanded cell population.
  • Cryopreserved: hUCT-MSCs ship frozen and require validated cryogenic storage (a −80 °C cryo freezer as standard; liquid nitrogen vapor phase ≤ −140 °C as best practice) to maintain viability until the point of use.

Stem Nova Network's 25M hUCT-MSC product is sourced from Wharton's jelly tissue from an AATB-accredited establishment with this tissue category within scope of accreditation. It is an individualized product that is not FDA-approved. Practitioners should consult with patients' primary care providers regarding the use of this product.

Side-by-Side: Exosomes vs. UCT-MSCs

Category Exosomes (EVs) UCT-MSCs (Living Cells)
What it is Extracellular vesicle — cell-free, non-living Living multipotent mesenchymal stromal cell
Size 30–150 nm 15–30 μm (roughly 100–500× larger)
Replication Cannot replicate or differentiate Self-renewing; capable of differentiation
Tissue source Conditioned media from cultured MSCs Wharton's jelly (umbilical cord tissue)
Manufacturing 3D bioreactor culture → isolation → NTA-verified count 3D bioreactor culture → harvest → viability testing
Key quality metric NTA particle count per vial Cell count + viability percentage (95–98%)
Storage −80 °C; cold chain validated −80 °C cryo freezer (standard); liquid nitrogen vapor phase ≤ −140 °C (best practice)
Shipping Frozen, temperature-monitored Frozen on dry ice, temperature-monitored
Regulatory framework HCT/P under 21 CFR Part 1271; topical cosmetic use labeling HCT/P under 21 CFR Part 1271; individualized, not FDA-approved
COA documentation NTA concentration, sterility (21 CFR 610.12), endotoxin (LAL, USP <85>), mycoplasma Cell count, viability, sterility (21 CFR 610.12), endotoxin (LAL, USP <85>), mycoplasma, ISCT identity markers
Minimum order No minimum (Stem Nova Network) No minimum (Stem Nova Network)

Key Differences That Matter for Your Practice

1. Manufacturing Environment Shapes the Product

Not all biologics are manufactured equally. The culturing environment — whether cells are expanded in a traditional two-dimensional (2D) flask or a three-dimensional (3D) bioreactor — has a significant effect on the resulting product.

In 2D culture, cells grow as a flat monolayer on a plastic surface. This is the conventional method, but it does not replicate the three-dimensional tissue environment cells occupy in the body. 3D bioreactor systems (including hollow-fiber, microcarrier, and spheroid formats) allow cells to grow in a spatial arrangement closer to their native state, which published literature has associated with greater secretome yield — some studies cite up to 20× more secretome output compared to 2D methods (manufacturer-reported data; independent verification recommended).

This distinction matters because both exosome concentration and MSC quality are downstream of the manufacturing process. When evaluating a supplier, asking whether they use 2D or 3D culture is one of the most informative questions a practitioner can ask.

2. How Concentration Is Verified

For exosome products, the most credible verification method is Nanoparticle Tracking Analysis (NTA). NTA uses laser light scattering and Brownian motion tracking to measure individual particles in solution, providing both a size distribution profile and a concentration count. Without NTA data on a COA, an exosome count is an estimate, not a measurement.

For hUCT-MSC products, the relevant metrics are total cell count and viability percentage. Viability is typically assessed via trypan blue exclusion, and results should appear on every lot COA. The viability figure tells you what percentage of cells in the vial are alive at the time of testing.

Supplier question to ask: "Is your exosome particle count NTA-verified on each lot COA, or is it an extrapolated estimate?" For stem cells: "What is the viability percentage on the most recent lot COA, and what method was used to measure it?"

3. Dual-Lab COA vs. Single-Lab COA

A Certificate of Analysis documents the testing results for a specific lot. Most suppliers issue a COA from one laboratory. A dual-lab COA means the same lot was tested independently by two separate labs, with both results documented. This adds a layer of verification that a single-lab report cannot provide — if both labs return consistent results, practitioners have higher confidence in the data.

This applies equally to exosome and MSC products. When evaluating any wholesale biologic supplier, asking whether COA testing is performed by one lab or two is a straightforward quality differentiator.

4. Regulatory Classification: Same Framework, Different Use Cases

Both exosome and UCT-MSC products are regulated under 21 CFR Part 1271, which governs human cells, tissues, and cellular and tissue-based products (HCT/Ps). Facilities manufacturing these products should be FDA-registered and operating under current Good Tissue Practice (cGTP) — not current Good Manufacturing Practice (cGMP), which applies to pharmaceutical drug manufacturing and is a different regulatory framework.

Practitioners should be aware that neither exosome nor UCT-MSC products currently carry FDA approval. Any supplier marketing these products as "FDA-approved" is making a claim that does not reflect the current regulatory landscape. The appropriate trust claims to verify are: FDA-registered facility, cGTP-compliant under 21 CFR Part 1271, and state-licensed.

5. Storage and Cold Chain Requirements

Both product categories are cold-chain-dependent, but the requirements differ:

  • Exosomes: Stored at −80 °C. Exosome stability is sensitive to temperature fluctuations — freeze-thaw cycles can degrade vesicle integrity and alter particle size distribution. Suppliers should ship with validated cold-chain packaging and include temperature monitoring.
  • UCT-MSCs: Store in a −80 °C cryo freezer, the standard. If your practice has it, liquid nitrogen vapor-phase storage at ≤ −140 °C is best practice. Because these are living cells, viability degrades if storage conditions are not maintained. Thawing protocols matter — improper thawing can reduce the viable cell count before a product is ever used.

Practices adding either product category should assess whether their existing storage infrastructure meets these requirements or whether an equipment investment is needed.

What to Evaluate Before Sourcing Either Product

  • Is the manufacturing facility FDA-registered?
  • Is the facility cGTP-compliant under 21 CFR Part 1271?
  • Does the supplier use 3D or 2D culturing?
  • Is particle count (exosomes) NTA-verified on each lot COA?
  • Is cell viability (MSCs) documented with a specific percentage on each lot COA?
  • Is COA testing performed by one lab or two independent labs?
  • For UCT-MSC: is the tissue sourced from an AATB-accredited establishment with the tissue category in scope?
  • Does the supplier document cumulative population doublings for MSC products?
  • Is the product shipped with validated cold-chain packaging and temperature monitoring?
  • Does the supplier provide clinician-directed support for storage, handling, and documentation?

Ready to Evaluate Wholesale Biologics?

Request product documentation, COA samples, and pricing for your practice.

Apply for a Wholesale Account Contact Our Team

Frequently Asked Questions

What is the difference between exosomes and stem cells?
Exosomes are nanoscale extracellular vesicles (30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are cell-free and cannot replicate or differentiate. Mesenchymal stem cells (MSCs) are living, multipotent cells capable of self-renewal and differentiation. They are significantly larger (15–30 μm) and require cryogenic storage to maintain viability. In a wholesale biologics context, exosomes are counted via NTA and MSCs are measured by cell count and viability percentage.
Are exosome and stem cell products FDA-approved?
Neither exosome nor UCT-MSC products currently carry FDA approval. Both are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. Practitioners should verify that a supplier's manufacturing facility is FDA-registered and cGTP-compliant. Any supplier claiming "FDA-approved" status for these product categories is making an inaccurate claim.
What is the difference between cGTP and cGMP?
Current Good Tissue Practice (cGTP) is the quality framework under 21 CFR Part 1271 that governs the manufacturing of human cells, tissues, and cellular and tissue-based products. Current Good Manufacturing Practice (cGMP) is a separate framework that applies to pharmaceutical drug manufacturing. Biologic tissue products such as exosomes and UCT-MSCs fall under cGTP, not cGMP. A supplier citing cGMP compliance for these products may be referencing the wrong regulatory standard.
How should exosomes and stem cells be stored?
Exosomes are stored at −80 °C and are sensitive to freeze-thaw cycles that can degrade vesicle integrity. UCT-MSCs require a −80 °C cryo freezer (standard) or liquid nitrogen vapor phase at ≤ −140 °C (best practice), and have specific thawing protocols that must be followed to preserve cell viability. Both product categories require validated cold-chain shipping with temperature monitoring.
What is NTA and why does it matter for exosomes?
Nanoparticle Tracking Analysis (NTA) is an instrument-based method that measures individual exosome particles in solution using laser light scattering and Brownian motion tracking. It provides both a size distribution profile and a verified concentration count. Without NTA, an exosome particle count listed on a product label is an estimate or extrapolation, not a measurement. Practitioners should verify that NTA data appears on each lot Certificate of Analysis.
What is a dual-lab COA?
A dual-lab Certificate of Analysis means the same production lot was tested independently by two separate laboratories, and both sets of results are documented. This provides a level of verification that a single-lab COA cannot. If both labs return consistent results for particle count, sterility, endotoxin, and mycoplasma, it increases confidence that the testing data accurately reflects the product.
Can a practice offer both exosomes and stem cells?
Yes. Many practices integrate both product categories, as they serve different applications. Exosome biologics (in a topical cosmetic context) and UCT-MSC products (as individualized, clinician-directed applications) have different regulatory requirements, storage needs, and documentation standards. Practices considering both should evaluate whether they have the infrastructure, training, and compliance documentation to support each category appropriately.
Regulatory Disclaimer: Exosome products referenced in this article are classified for topical cosmetic use only. hUCT-MSC products are individualized and not FDA-approved; practitioners should consult with patients' primary care providers regarding their use. Neither product category is intended to diagnose, treat, cure, or prevent any disease. All products are manufactured in an FDA-registered, cGTP-compliant (21 CFR Part 1271), state-licensed facility in the United States. This article is intended for licensed medical professionals (MD, DO, NP, PA) and does not constitute medical advice.